Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

Phase II Study of Oxaliplatin and CPT-11 as First Line Treatment for Extensive Stage Small Cell Lung Cancer

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00316433

Enrollment

Registered

2006-04-20

Start date

2005-02-28

Completion date

2007-01-31

Last updated

2007-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

Brief summary

The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.

Interventions

DRUGIrinotecan (CPT-11)

DRUGOxaliplatin (Eloxatin)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Previously untreated extensive small cell lung cancer * No prior chemotherapy * No prior radiotherapy except for the treatment of brain metastases

Exclusion criteria

* Prior treatment for extensive stage small cell lung cancer * Known hypersensitivity to any of the components of oxaliplatin or CPT-11 * Greater than grade 2 peripheral neuropathy * Known HIV or Hepatitis B or C (active, previously treated or both)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026